A placebo-controlled, double-blind, randomised trial of magnesium-pyridoxal-5'-phosphate-glutamate for hypercholesterolaemia and other clinical-chemical risk factors of cardiovascular disease in a primary care setting.

What Was Tested

Researchers studied Glutamine in this randomized controlled trial publication.

Magnesium-pyridoxal-5'-phosphate-glutamate (MPPG) has been found to have a positive influence on TC levels and other clinical-chemical values in some selected populations.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Glutamine and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Glutamine.

The comparison arm used a placebo, so changes seen with Glutamine could be set against what happens without it.

Clinical-chemical parameters were assessed at 1, 3, 6, 9 and 12 months (t1, t2, t3, t4, t5).

What Was Measured

Magnesium-pyridoxal-5'-phosphate-glutamate (MPPG) has been found to have a positive influence on TC levels and other clinical-chemical values in some selected populations.

Topics PubMed links to this paper include Apolipoproteins A, Cardiovascular Diseases, Cholesterol, LDL, Glutamine, Hypercholesterolemia, Hypolipidemic Agents and Netherlands.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glutamine.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2001 (European journal of clinical pharmacology), a journal based in Germany.

More context: all human trials.